Assess cancer risk and identify opportunities for increased surveillance

Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer in the world. While HCC can be effectively treated in its early stages, most patients are not diagnosed until they are symptomatic and at higher grades and stages, when the disease is less responsive to therapies. Laboratory testing and imaging can identify at-risk patients needing increased surveillance to help aid in early diagnosis.

Key testing

HCCGS | Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum

DCP | Des-Gamma-Carboxy Prothrombin, Serum

• Assesses risk for developing hepatocellular carcinoma (HCC) in patients with chronic liver disease.
• Aids in the monitoring of HCC patients post-therapy if the des-gamma-carboxy prothrombin level was elevated prior to therapy.

L3AFP | Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum

• Distinguishes between HCC and chronic liver disease.
• Monitors individuals with hepatic cirrhosis from any etiology for progression to HCC.
• Monitors individuals with a positive family history of hepatic cancer for development of HCC.
• Monitors for development of HCC in individuals within specific ethnic and gender groups who do not have hepatic cirrhosis but have a confirmed diagnosis of chronic hepatitis B infection acquired early in life, including African males above age 20, Asian males above age 40, and Asian females above age 50.

AFP | Alpha-Fetoprotein (AFP) Tumor Marker, Serum

• Monitors patients undergoing cancer therapy, especially for hepatocellular carcinoma.

Identify cases that would be missed by AFP alone

In a study of 74 patients, the use of a three-biomarker panel test detected 67 HCC cases (91%). The use of AFP alone would have detected only 45 HCC cases (60%), or 22 fewer cases than using a panel.